Eric Hsu
Fortuna: 3 $ al 31/05/2026
Fortuna: 3 $ al 31/05/2026
Eric C.
Hsu is Senior VP-Pre-Clinical Research & Development at InMed Pharmaceuticals, Inc. since 2018.
Formerly, Dr. Hsu was VP-Scientific Affairs, Research & Operations at enGene, Inc. from 2002 to 2018.
Education includes an undergraduate degree from McGill University and a doctorate from the University of Toronto conferred in 1999.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 19/12/2025 | 2 ( 0 % ) | 3 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Director Técnico/Científico/I+D | 13/03/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which develops non-viral gene therapies | Director de Operaciones | 01/01/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
InMed Pharmaceuticals, Inc.
InMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures prescription-based products for dermatology and ocular diseases | Health Technology |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which develops non-viral gene therapies | Health Technology |
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.